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Summary
Background.  —  Cardiomyocytes  produce  a  wide  variety  of  bioactive  molecules  that  regulate
numerous  physiological  and  pathophysiological  processes.  Recently,  it  has  been  recognized  thatGalectin-3; changes in  microribonucleic  acid  (miRNA)  expression  may  lead  to  cardiac  dysfunction.
NT-proBNP;
Cardiovascular
disease;
Heart  failure
Aims. —  To  assess  the  expression  of  circulating  miRNAs  (miR-1,  miR-21  and  miR-208a)  in  patients
with symptomatic  heart  failure  (HF),  and  to  investigate  the  relationship  between  expression
of these  miRNAs  and  secretion  of  N-terminal  pro-B-type  natriuretic  peptide  (NT-proBNP)  and
galectin-3.
Abbreviations: HF, heart failure; LVEF, left ventricular ejection fraction; miRNA or miR, microribonucleic acid; NT-proBNP, N-terminal
rohormone of B-type natriuretic peptide; NYHA, New York Heart Association; qRT-PCR, quantitative real-time polymerase chain reaction.
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Methods.  —  Thirty-ﬁve  patients  in  New  York  Heart  Association  (NYHA)  class  II/III  (age:
68.8 ±  13.0  years)  and  26  patients  in  NYHA  class  IV  (age:  72.0  ±  10.4  years)  hospitalized  in
the intensive  coronary  care  unit  participated  in  the  study.  Serum  concentrations  of  miRNAs
were measured  by  quantitative  real-time  polymerase  chain  reaction.  Basic  biochemical  assays
were carried  out,  and  NT-proBNP  and  galectin-3  concentrations  were  measured  in  all  serum
samples.
Results. —  miR-1  was  downregulated  in  patients  with  symptomatic  HF  and  its  expression
decreased  with  severity  of  NYHA  class  (P  =  0.007).  In  contrast,  overexpression  of  miR-21  was
seen in  all  patients,  independent  of  HF  severity.  Results  suggest  no  miR-208a  leakage  into  the
circulation  in  patients  with  symptomatic  HF.  There  was  an  inverse  relationship  between  miR-1
expression  and  NT-proBNP  concentration  (Spearman’s  rank  correlation  coefﬁcient  [r]  =  —0.389;
P =  0.023)  in  patients  in  NYHA  class  II/III.  Overexpression  of  miR-21  correlated  signiﬁcantly  with
galectin-3  concentration  (r  =  0.422;  P  =  0.032).
Conclusion.  —  Dysregulation  of  miR-1  and  miR-21  expression  may  be  essential  for  the  develop-
ment of  HF;  miR-1  might  become  a  biomarker  for  predicting  HF  exacerbation.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Justiﬁcation.  — Les  cardiomyocytes  produisent  une  large  variété  de  molécules  bioactives  régu-
lant différents  processus  physiologiques  et  physiopathologiques.  Récemment,  il  a  été  montré
que l’expression  des  modiﬁcations  d’ARN-mi  pouvait  conduire  à  une  dysfonction  cardiaque.
Objectifs.  — Évaluer  l’expression  des  ARN-mi  circulant  (miR-1,  miR-21  et  miR-208a)  chez  des
patients ayant  une  insufﬁsance  cardiaque  symptomatique.  Nous  avons  également  investigué  la
relation entre  l’expression  de  ces  micro-ARN  et  la  sécrétion  de  NT-pro-BNP  et  de  galectine-3.
Méthode.  — Trente-cinq  patients  en  classe  fonctionnelle  NYHA  II  à  III  (âge  moyen  :  68,8  ±  13  ans)
et 26  patients  en  classe  fonctionnelle  NYHA  IV  (âge  moyen  :  72,0  ±  10,4  ans)  ont  été  hospitalisés
dans une  unité  de  soins  intensifs  cardiaque  et  ont  participé  à  cette  étude.  Les  concentra-
tions sériques  de  micro-ARN  ont  été  mesurées  par  méthode  de  PCR  quantitative.  L’évaluation
biochimique  a  été  effectuée  dans  les  prélèvements  sanguins  initiaux  avec  détermination  des
taux de  NT-pro-BNP  et  de  galectine-3.
Résultats.  —  miR-1  était  régulé  de  fac¸on  négative  chez  les  patients  ayant  une  insufﬁsance  car-
diaque symptomatique  et  leur  expression  décroissait  avec  la  sévérité  de  la  classe  fonctionnelle
NYHA (p  =  0,007).  En  revanche,  la  surexpression  de  miR-21  était  observée  chez  tous  les  patients,
indépendamment  de  la  sévérité  de  l’insufﬁsance  cardiaque.  Nos  résultats  suggèrent  qu’il  n’y  a
pas de  libération  de  miR-208a  dans  la  circulation  sanguine  chez  les  patients  ayant  une  insuff-
isance cardiaque  symptomatique.  Nous  avons  noté  une  relation  inverse  entre  l’expression  de
miR-1 et  les  concentrations  de  NT-pro-BNP  (coefﬁcient  de  corrélation  de  Spearman  [r]  =  0,389
; p  =  0,023)  chez  les  patients  en  classe  fonctionnelle  NYHA  II  ou  III.  La  surexpression  miR-21  est
corrélée  avec  les  concentrations  de  galectine-3  (r  =  0,422  ;  p  =  0,032).
Conclusion.  —  La  dysrégulation  de  l’expression  de  miR-1  et  miR-21  pourrait  être  essentielle
pour l’apparition  d’une  insufﬁsance  cardiaque  ;  miR-1  pourrait  dans  ces  conditions  devenir  un
biomarqueur  prédisant  les  poussées  d’insufﬁsance  cardiaque.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Microribonucleic  acids  (miRNAs)  are  recently  discovered,
small,  endogenous,  single-stranded,  non-coding  RNAs  com-
prising  18—25  nucleotides.  They  are  initially  transcribed  as
primary-miRNA  with  a  characteristic  stem-loop  structure.
The  primary-miRNA  stem-loop  structure  is  cleaved  by  the
enzyme  Drosha  to  ∼70  nucleotides  in  length  within  the
nucleus,  and  is  called  precursor-miRNA.  Precursor-miRNAs
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mre  then  exported  from  the  nucleus  into  the  cytoplasm,
here  the  mature  miRNA  strands  regulate  gene  expression
ost  transcriptionally  [1].
More  than  600  miRNAs  have  been  discovered;  they  par-
icipate  in  various  physiological  processes,  including  heart
evelopment,  but  are  also  involved  in  the  pathogenesis  of
eart  failure  (HF),  myocardial  hypertrophy  and  arrhythmia
2,3].  Cardiac  ﬁbroblasts  play  a  key  role  in  the  adverse
yocardial  remodelling  that  occurs  with  hypertension,
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yocardial  infarction  and  HF.  The  involvement  of  miRNAs  in
hese  pathological  processes  has  been  recently  recognized.
ndeed,  altered  miRNA  expression  during  cardiac  remod-
lling  has  been  reported  in  mice  and  humans  [4]. Aberrant
xpression  of  selected  miRNAs  has  been  linked  with  various
athological  conditions  such  as  cardiac  ﬁbrosis  [5].  Recent
vidence  suggests  that  miRNAs  are  differentially  expressed
n  the  failing  myocardium  and  play  an  important  role  in  the
rogression  of  HF  [6,7].  miRNAs  are  fundamentally  involved
n  and  have  an  effect  on  cardiac  ﬁbrosis  [5,8].  In  addition,
iRNA  controls  cardiac  ﬁbroblast  differentiation  [9].
Among  the  numerous  miRNAs  reported  to  inﬂuence  the
rocess  of  maladaptive  cardiac  remodelling,  the  strongest
reclinical  and  clinical  data  appear  to  support  the  roles  of
iR-1,  miR-21  and  miR-208  in  this  process  [10].  miR-1  is
ne  of  the  most  abundant  miRNA  in  the  heart,  and  plays  a
rotective  role  against  cardiac  hypertrophy  or  HF  by  regu-
ating  several  hypertrophy-associated  genes,  which  include
ranscription  factors,  receptor  ligands,  apoptosis  regulators
nd  ion  channels,  as  well  as  exacerbating  arrhythmogenesis
hen  overexpressed  [10—14].  Predominantly  expressed  in
ardiac  ﬁbroblasts,  miR-21  is  one  of  the  most  greatly  upre-
ulated  miRNAs  during  cardiac  hypertrophy;  miR-21  induces
ardiac  ﬁbrosis  and  protects  cardiomyocytes  against  apo-
tosis.  Interestingly,  pharmacological  antagonism  of  miR-21
uppresses  cardiac  remodelling  after  pressure  overload  in
he  heart  [13].  Furthermore,  in  experimental  studies,  miR-
08a  was  sufﬁcient  to  induce  cardiac  remodelling  and
odulate  the  expression  of  hypertrophy-associated  genes,
nd  the  systemic  delivery  of  miR-208a  inhibitors  prevented
athological  myosin  switching  and  cardiac  remodelling  while
mproving  cardiac  function  and  survival  [10,12].
The  aims  of  this  study  were  to  assess  the  level  of  expres-
ion  of  miRNA-1,  miRNA-21  and  miRNA-208a  in  the  sera  of
atients  with  symptomatic  HF,  and  to  evaluate  the  relation-
hip  between  serum  miRNAs  and  the  serum  concentrations
f  galectin-3  and  N-terminal  prohormone  of  B-type  natri-
retic  peptide  (NT-proBNP)  in  relation  to  the  severity  of
ecompensated  HF.
ethods
tudy population
ixty-one  patients  hospitalized  for  symptomatic  HF  in  the
st  Chair  and  Department  of  Cardiology,  Medical  University
f  Warsaw,  between  October  2013  and  August  2014  were
nrolled  in  this  prospective,  single-centre  registry.  Symp-
omatic  HF  comprised  acute  decompensated  heart  failure
 de  novo  or  decompensation  of  chronic  heart  failure  [15]
 as  well  as  symptomatic  chronic  HF,  with  New  York  Heart
ssociation  (NYHA)  class  ≥  II.
Patients  with  symptomatic  HF  requiring  hospitalization
ere  included  within  24  hours  of  admission.  The  inclusion
riteria  also  involved  clinical  or  radiological  signs  of  pul-
onary  congestion  and  left  ventricular  ejection  fraction
LVEF)  <50%,  computed  according  to  Simpson’s  method  [16].
Patients  with  acute  coronary  syndromes,  active  infec-
ion,  Cushing’s  syndrome,  primary  hyperaldosteronism,
ddison’s  disease,  liver  cirrhosis,  acute  renal  failure,  para-
eoplastic  syndromes,  subarachnoid  haemorrhage,  chronic
t
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ung  diseases,  acute  and  chronic  pulmonary  embolism,  and
yopathies  were  excluded  from  the  study.
Data  on  time  of  chronic  HF  diagnosis,  risk  factors,  car-
iovascular  conditions,  family  history  and  previously  used
edications  were  collected.  All  enrolled  patients  underwent
 physical  examination,  with  special  emphasis  on  clinical
eatures  of  HF,  an  electrocardiogram  and  routine  laboratory
ests.
The  local  ethics  committee  approved  the  protocol  of  the
tudy,  and  all  patients  provided  written  informed  consent.
chocardiographic studies
ach  patient  underwent  a  complete  echocardiographic
xamination  using  an  iE33  ultrasound  system  (Philips,
msterdam,  Netherlands).  LVEF  was  calculated  according  to
impson’s  method  [16].
ample collection
lood  samples  were  collected  during  the  24  hours  after
dmission.  Blood  samples  were  collected  after  overnight
asting  into  plastic  tubes  with  clot  activator.  Large  gauge
eedles  were  used  to  avoid  potential  platelet  activation  and
iRNA  release,  as  suggested  by  Witwer  et  al.  [17].
irculating RNA extraction
otal  RNA  was  extracted  from  300  L  of  serum  using
 commercial  column-based  system  (NucleoSpin® miRNA
lasma  kit;  Macherey-Nagel,  Düren,  Germany),  according
o  the  manufacturer’s  instructions.  Before  RNA  isolation,
erum  samples  were  thawed  and  vortexed.  Total  RNA  was
luted  by  adding  30  L  of  ribonuclease-free  water  to  the
embrane  of  the  spin  column.  RNA  was  stored  at  −80 ◦C
ntil  further  analysis.  A  ﬁxed  volume  of  4 L  RNA  solution
rom  the  30  L  RNA  isolation  eluate  was  put  into  the  reverse
ranscription  reaction.
irculating miRNA reverse transcription and
mpliﬁcation
omplementary  deoxyribonucleic  acid  (cDNA)  synthesis  was
erformed  with  the  Universal  cDNA  Synthesis  kit  (Exiqon,
edbaek,  Denmark)  according  to  the  manufacturer’s  proto-
ol.  The  reaction  volume  was  20  L.  Endogenous  abundance
f  miRNA  was  measured  using  quantitative  real-time  poly-
erase  chain  reaction  (qRT-PCR)  on  the  ViiATM 7  Real-Time
CR  System  (Thermo  Fisher  Scientiﬁc,  Waltham,  MA,  USA).
he  triplicate  reactions  in  15  L  were  carried  out  using  Exi-
ENT  SYBR® Green  Master  Mix  (Exiquon,  Vedbaek,  Denmark)
ith  the  locked  nuclei  acid  (LNATM)  primer  sets  for  miRNA-1
MIMAT0000416),  miRNA-21-5p  (MIMAT0000076)  and  miRNA-
08a  (MIMAT0000241),  plus  miRNA-103-3p  (MIMAT0000101)
s  an  internal  control.  In  each  reaction,  6  L  of  10  ×
iluted  cDNA  was  used.  Thermal  cycling  consisted  of  an
nitial  denaturation  followed  by  50  cycles  of  ampliﬁcation.
 melt  curve  was  performed  after  each  cycle  to  indicate
he  speciﬁcity  of  the  primers.  The  threshold  cycle  (Ct)  for
ach  reaction  was  determined,  deﬁned  as  a  cycle  number
t  which  exponential  phase  of  the  ampliﬁcation  plot  crosses
he  threshold,  signiﬁcantly  above  the  background.  If  the  Ct
e
u
m
S
w
R
P
S
i
p
m
2
a
c
g
E
m
s
d
g
c
o
e
(
a
[
P
c
(
o
t
o
a
t
s
t
R
b
T
e
f
N
t
s
p
t
I
o
s
cMicroribonucleic  acids  and  heart  failure  
value  was  >40,  the  miRNA  concentration  was  considered
undetectable.  Relative  expression  of  investigated  miRNAs
compared  with  healthy  volunteers  was  calculated  using  the
Ct  method,  the  most  usual  way  to  analyse  gene  expres-
sion  experiments.  For  each  sample,  Ct  was  obtained,
which  indicates  the  difference  in  Ct  values  between  the
miRNA  of  interest  and  the  endogenous  control  (miR-103-3p)
(Ct  =  CtmiR-x −  CtmiR-103).  Then,  the  mean  Ct  value  for  the
control  group  was  calculated  and  subtracted  from  the  Ct
value  obtained  for  the  individuals  from  the  experimental
group  (Ct = Ctex −  Ctco).  To  ﬁnd  the  relative  expres-
sion,  the  fold  value  was  calculated  using  the  2-Ct formula.
A  fold  value  (2-Ct)  lower  or  higher  than  1  indicates  down-
or  upregulation,  respectively,  compared  with  the  healthy
controls.
The  results  are  presented  as  fold  change  in  relation  to
the  miRNA  expression  in  the  serum  samples  of  the  con-
trol  subjects,  who  were  17  age-  and  sex-matched  healthy
volunteers,  age:  59  ±  12.4  years;  13  (76%)  were  men.  Nor-
malization  for  variations  in  RNA  input  was  conducted  using
miR-103-3p,  which,  in  our  samples,  varied  little  between
patients,  with  a  coefﬁcient  of  variation  =  7.94%.  Moreover,
this  miRNA  was  found  to  be  stably  expressed  in  plasma.
In  addition,  we  analysed  the  expression  of  miR-16,  but  it
occurred  to  be  less  favourable,  as  the  coefﬁcient  of  variation
occurred  to  be  higher  (11.6%).
Biochemical analysis
Blood  samples  were  collected  after  overnight  fasting  into
plastic  tubes  with  clot  activator.  After  centrifugation,  part
of  the  serum  samples  were  used  for  determination  of
the  concentrations  of  creatinine,  high-sensitivity  C-reactive
protein,  NT-proBNP,  troponin  I;  the  remaining  serum  was
immediately  frozen  at  −70 ◦C  for  later  measurements  of  the
concentration  of  galectin-3.  Serum  galectin-3  concentration
was  measured  using  the  reagents  and  instrument  from  the
VIDAS® family  (bioMérieux  SA,  Marcy-l’Étoile,  France).  The
assay  principle  combines  a  one-step  immunoassay  sandwich
method  with  ﬁnal  ﬂuorescent  detection  (enzyme-linked  ﬂu-
orescence  assay  [ELFA]).  The  concentrations  of  creatinine,
high-sensitivity  C-reactive  protein,  troponin  I  and  NT-proBNP
were  measured  using  the  Flex® Reagent  Cartridge  and  the
Dimension  Xpand  instrument  (Siemens  Health  Care  Diagnos-
tics,  Erlangen,  Germany).
Statistical analysis
For  statistical  analyses,  the  data  analysis  software  sys-
tem  STATISTICA,  version  10  (StatSoft,  Inc.,  Tulsa,  OK,  USA)
was  used.  Continuous  variables  were  tested  for  normal
distribution  by  the  Shapiro-Wilk  test.  Results  for  nor-
mally  distributed  continuous  variables  are  expressed  as
means  ±  standard  deviations,  and  we  used  the  unpaired
Student’s  t  test  to  compare  mean  values.  Continuous
variables  with  non-normal  distribution  are  presented  as
median  values  and  interquartile  ranges  (range  from  the
25th  to  the  75th  percentile).  Between-group  comparisons
of  distributions  were  performed  using  the  Mann-Whitney
U  test  and  Wilcoxon’s  signed-rank  sum  test.  Correlations
among  continuous  variables  were  assessed  using  Spearman’s
rank  correlation  coefﬁcient  [r].  Categorical  variables  are
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xpressed  as  numbers  (percentages)  and  were  compared
sing  Fisher’s  exact  test.  To  evaluate  the  expression  levels  of
iRNAs  circulating  within  the  two  groups,  we  decided  to  use
tudent’s  t  test  for  two  independent  groups.  P-values  <  0.05
ere  considered  statistically  signiﬁcant.
esults
atients’ characteristics
ixty-one  patients  were  divided  into  two  subgroups  accord-
ng  to  NYHA  functional  class.  The  ﬁrst  group  included  35
atients  with  cardiac  functional  classes  II  and  III,  with  a
ean  age  of  68.8  ±  13.0  years;  the  second  group  included
6  patients  with  cardiac  functional  class  IV,  with  a  mean
ge  of  72.0  ±  10.4  years.  There  were  no  statistically  signiﬁ-
ant  differences  in  terms  of  age  and  sex  between  these  two
roups  (Table  1).
xpression of miRNA
iRNA-1  was  downregulated  in  the  serum  of  patients  with
ymptomatic  HF.  The  degree  of  expression  of  miRNA-1
ecreased  with  the  severity  of  NYHA  class.  This  effect  was
reater  in  patients  in  NYHA  class  IV  than  in  those  in  NYHA
lass  II/III  (P  =  0.007)  (Fig.  1A).  In  contrast,  miR-21  was
verexpressed  in  patients  with  symptomatic  HF,  and  the
xpression  of  miR-21  was  independent  of  disease  severity
Fig.  1B).  In  both  groups  of  patients  (NYHA  classes  II/III
nd  IV),  the  concentration  of  miR-21  was  the  same  (2.00
1.01—4.84]  change  fold  vs.  2.092  [1.48—4.46]  change  fold;
 =  0.95).  The  qRT-PCR  results  obtained  for  miR-208a  indi-
ated  no  ampliﬁcation  or  ampliﬁcation  was  irreproducible
standard  deviation  for  amplifying  replicates  >0.5).  More-
ver,  we  observed  multiple  peaks  in  the  melting  curves  in
he  reactions  with  ampliﬁcation,  meaning  that  the  quality
f  the  data  was  low  and  inconsistent  with  speciﬁc  and  reli-
ble  detection.  Thus,  in  our  study,  there  is  little  evidence  for
he  presence  of  miR-208a  in  the  analysed  plasma  samples,
uggesting  no  miR-208a  leakage  from  the  injured  heart  into
he  circulation  in  the  control  and  symptomatic  HF  groups.
elationship between miRNA expression and
iomarkers of cardiac function
o  examine  whether  changes  in  miRNA  expression  inﬂu-
nce  cardiac  ﬁbrosis  and  neurohormonal  activation  in  the
ailing  heart,  the  concentrations  of  serum  galectin-3  and
T-proBNP  were  determined.  We  observed  signiﬁcant  nega-
ive  correlation  between  decreasing  miR-1  expression  and
erum  NT-proBNP  concentration  (r  =  −0.389;  P  =  0.023)  in
atients  in  NYHA  class  II/III  (Fig.  2A).  However,  this  correla-
ion  was  not  statistically  signiﬁcant  in  patients  in  NYHA  class
V  (r  =  0.025;  P  =  0.90).  It  must  also  be  noted  that  we  did  not
bserve  any  relationship  between  changes  in  miR-1  expres-
ion  and  serum  galectin-3  concentration  in  patients  in  NYHA
lass  II/III  (r  =  —0.299;  P  =  0.08)  or  NYHA  class  IV  (r  =  —0.109; =  0.60).
Overexpression  of  miR-21  was  signiﬁcantly  correlated
ith  serum  galectin-3  concentration  in  patients  in  NYHA
lass  IV  (r  =  0.422;  P =  0.032;  Fig.  2B).  In  patients  in  NYHA
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Table  1  Baseline  characteristics  of  patients  with  symptomatic  heart  failure  (n  =  61).
NYHA  class  II/III  (n  =  35)  NYHA  class  IV  (n  =  26)  P-value
Personal  factors
Age  (years)  68.8  ±  13.0  72.0  ±  10.4  0.46
Men  80  (28) 76.9  (20) 0.23
Hospitalization  in  the  last  year 65.7  (23) 61.5  (16) 0.27
Risk  factors
LVEF  (%)  37  (25—52)  25  (20—35)  0.011
Current  smoking  17.1  (6)  23.1  (6)  0.45
Hypercholesterolaemia  22.9  (8)  26.9  (7)  0.42
Chronic  kidney  disease
Stage  3  (eGFR  <  60  mL/min/1.73  m2)  48.6  (17)  53.8  (14)  0.31
Stage  4  (eGFR  <  30  mL/min/1.73  m2)  2.9  (1)  15.4  (4)  0.65
Creatinine  (mg/dL)  1.31  ±  0.62  1.46  ±  0.46  0.27
Diabetes  mellitus  37.1  (13)  38.5  (10)  0.34
Previous  cardiovascular  disease
Coronary  artery  disease  68.6  (24)  73.1  (19)  0.26
Peripheral  artery  disease  8.6  (3)  7.7  (2)  0.59
Atrial  ﬁbrillation  42.9  (15)  53.8  (14)  0.31
Stroke  20  (7)  15.4  (4)  0.49
Medications  at  presentation
ACE  inhibitor 74.3  (26)  57.7  (15)  0.26
Beta-blocker  68.6  (24) 73.1  (19)  0.26
Aldosterone  antagonist 37.1  (13) 42.3  (11) 0.35
Digoxin  5.7  (2) 23.1  (6)  0.57
Loop  diuretic 84.6  (22)  74.3  (26)  0.22
Risk  markers  at  baseline
Pulse  rate  (bpm)  89.6  ±  26.3  94.8  ±  25.6  0.48
Systolic  blood  pressure  (mmHg)  129.2  ±  27.9  125.8  ±  24.9  0.63
Laboratory
hsCRP  (mg/L)  8  (2.9—47.7)  13.7  (7.2—56)  0.08
Troponin  I  (ng/mL)  0.017  (0—1.153)a 0.12  (0.034—0.921)b 0.11
NT-proBNP  (pg/mL)  1960.5  (1147—5873)  8507  (3695—19,624)  0.001
Galectin-3  (ng/mL)  15.8  (10.3—21.4)  19.2  (15.4—25.6)  0.048
miR-1  (change  fold)  0.642  (0.281—1.49)  0.253  (0.148—0.46)  0.007
miR-21  (change  fold)  2.00  (1.01—4.84)  2.092  (1.48—4.46)  0.95
Data are expressed as mean ± standard deviation, number (%) or median (interquartile range [range from the 25th to the 75th per-
centile]); ACE: angiotensin-converting enzyme; eGFR: estimated glomerular ﬁltration rate; hsCRP: high-sensitivity C-reactive protein;
LVEF: left ventricular ejection fraction; miR: microribonucleic acid; NT-proBNP: N-terminal prohormone of B-type natriuretic peptide;
NYHA: New York Heart Association.
a Data available for 20 patients.
b Data available for 18 patients.
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nlass  II/III,  however,  we  did  not  observe  this  correla-
ion  (r  = −0.092;  P  =  0.60).  Overexpression  of  miR-21  did
ot  inﬂuence  the  concentration  of  NT-proBNP,  regardless
f  disease  severity:  r  =  −0.075  in  patients  in  NYHA  class
I/III  (P  =  0.67);  and  r =  0.182  in  patients  in  NYHA  class  IV
P  =  0.38).
It should  be  noted  that  there  was  a  signiﬁcant  posi-
ive  correlation  between  serum  creatinine  and  galectin-3
oncentrations  in  patients  in  NYHA  class  II/III  (r  =  0.441;
 =  0.008)  and  NYHA  class  IV  (r  =  0.640;  P  =  0.0006).  Interest-
ngly,  we  found  a  negative  association  between  creatinine
oncentrations  and  miR-1  expression  in  the  NYHA  class  II/III
D
T
proup  (r  =  −0.463;  P  =  0.005).  There  was  no  statistically  sig-
iﬁcant  association  between  miR-21  expression  and  renal
unction  variables.  Furthermore,  we  did  not  observe  signif-
cant  differences  between  the  NYHA  class  II/III  and  class  IV
roups  in  terms  of  troponin  concentrations  (0.017  [0—1.153]
g/mL  vs.  0.12  [0.034-0.921]  ng/mL,  respectively).
iscussionhe  main  ﬁnding  of  this  study  was  the  observation  that  in
atients  with  the  most  exacerbated  clinical  symptoms  of  HF
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Figure 1. A. Expression of microribonucleic acid-1 (miR-1) in
Figure 2. A. Correlations between serum N-terminal prohor-
mone of B-type natriuretic peptide (NT-proBNP) concentrations and
microribonucleic acid-1 (miR-1) expression in patients with symp-
tomatic heart failure in New York Heart Association (NYHA) class
II/III. B. Correlations between serum galectin-3 concentrations and
microribonucleic acid-21 (miR-21) expression in patients with symp-
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tpatients with symptomatic heart failure. B. Expression of microri-
bonucleic acid-21 (miR-21) in patients with symptomatic heart
failure. NYHA: New York Heart Association.
(NYHA  functional  class  IV),  miR-1  was  signiﬁcantly  downreg-
ulated.  miR-1  is  the  second  most  abundant  miRNA  in  the
human  heart  [18].  It  has  been  evaluated  mainly  in  acute
myocardial  infarction  studies,  showing  notable  upregulation
and  achievement  of  peak  concentrations  earlier  than  car-
diac  troponins  [19].  Evidence  of  its  expression  in  acute  HF
has  received  far  less  interest  so  far,  and  the  available  data
remain  controversial  [7,14,20—23].
We  have  presented  results  indicating  that  downregulat-
ion  of  the  expression  of  miRNA-1  is  correlated  with  the
increase  of  serum  NT-proBNP  concentration  in  patients  with
symptomatic  HF  in  NYHA  class  II/III.  As  there  were  no
patients  with  acute  myocardial  infarction  included  in  this
study,  the  miR-1  expression  pattern  was  not  inﬂuenced
by  the  presence  of  acute  ischaemia  or  myocardial  necro-
sis,  which  could  potentially  increase  the  expression  of  this
miRNA  type  [11].
NT-proBNP  is  a  well-established  biomarker  recommended
for  acute  HF  diagnosis  in  patients  presenting  with  acute  dys-
pnoea,  and  for  stratiﬁcation  of  risk  in  subjects  with  chronic
HF  [15].  To  date,  two  types  of  miRNAs  have  appeared  to  cor-
relate  positively  with  NT-proBNP:  miR-499  and  miR-423-5p
[24,25].  Recently,  the  concentrations  of  four  other  miRNAs,
i
a
iomatic heart failure in NYHA class IV. Spearman’s rank correlation
oefﬁcients (r) are indicated.
hich  were  increased  in  sera  of  patients  with  HF,  namely
iR-423-5p,  miR  320a,  miR-22  and  miR-92b,  were  combined
y  Goren  et  al.  into  a  single  ‘miRNA  score’,  which  was  also
igniﬁcantly  associated  with  elevated  serum  BNP  concentra-
ions  [26]. Another  miRNA  type  investigated  as  a  potential
iomarker  of  congestive  HF  was  miR-126,  which  was  sig-
iﬁcantly  downregulated  in  patients  with  ischaemic  heart
isease  and  congestive  HF,  being  negatively  correlated  with
NP  [27].
We observed  signiﬁcant  miR-1  downregulation  in  NYHA
lass  IV  patients  and  its  reverse  correlation  with  NT-proBNP,
 validated  prognostic  variable.  To  the  best  of  our  knowl-
dge,  these  data  demonstrate  for  the  ﬁrst  time  that
irculating  miR-1  may  be  a  novel  biomarker  for  predicting
he  exacerbation  of  HF.
Our  ﬁndings  correspond  with  observations  conﬁrming  the
nhibitory  effect  of  miR-1  on  cardiac  hypertrophy  [28].  In
ddition,  Zhao  et  al.  [29]  reported  an  increasing  modulat-
ng  effect  of  miR-1  on  cardiomyocyte  number.  miRNA-133
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s  another  muscle-speciﬁc  miRNA,  which  forms  a  bicistronic
luster  with  miRNA-1.  The  regulation  of  cardiomyocyte  apo-
tosis  by  miR-1  and  miRNA-133  has  also  been  suggested  by
u  et  al.  [30].  miR-1  and  miR-133  produced  opposing  effects
n  apoptosis,  induced  by  oxidative  stress  in  a  rat  embryonic
entricular  cell  line  or  in  neonatal  rat  ventricular  myocytes.
hese  experiments  provide  evidence  of  miR-1  being  pro-
poptotic  and  miR-133  being  antiapoptotic.
According  to  preclinical  studies,  downregulation  of  the
uscle-speciﬁc  miR-1  mediates  the  induction  of  pathologi-
al  cardiac  hypertrophy  [31].  Some  authors  have  suggested
hat  its  downregulation  may  also  induce  ventricular  tach-
arrhythmias  by  altering  the  expression  and  function  of
onnexin  43  located  in  gap  junctions  [20]. Some  reports
ave  suggested  that  the  concentrations  of  miR-1  are  lower
n  acute  HF,  which  is  in  line  with  our  results  [32].  How-
ver  other  observations  were  noted  in  the  study  by  Zhang
t  al.,  who  found  that  elevated  plasma  miR-1  concentrations
ay  predict  the  onset  of  HF,  and  are  negatively  correlated
ith  LVEF  (P  =  0.0001)  [14].  In  our  study,  we  did  not  ﬁnd  any
elationship  between  miR-1  concentrations  and  LVEF.  How-
ver,  Zhang  et  al.  [14]  selectively  enrolled  patients  after
cute  myocardial  infarction,  in  whom  the  miR-1  concentra-
ion  might  have  been  altered  by  the  ischaemia,  blurring  the
ause—effect  connection.
Another  important  ﬁnding  of  this  study  was  that  the
oncentrations  of  galectin-3,  a  novel,  promising  biomarker
f  adverse  cardiac  remodelling,  were  higher  in  the  NYHA
lass  IV  group  than  in  the  NYHA  class  II/III  group.  This  sol-
ble  -galactoside-binding  protein  released  by  activated
acrophages  is  involved  in  numerous  pathological  pro-
esses,  including  inﬂammation,  tumour  growth  and  ﬁbrosis
33,34].  Of  note,  we  found  a  signiﬁcant  correlation  between
alectin-3  and  NT-proBNP  concentrations,  consistent  with
ome  previous  reports  [35,36].
Interestingly,  in  the  group  of  chronic  HF  patients  with  the
ost  pronounced  clinical  symptoms  of  the  disease  (NYHA
unctional  class  IV),  we  observed  a  signiﬁcant  association
etween  galectin-3  and  miR-21  serum  concentrations.  miR-
1  is  one  of  the  most  highly  expressed  miRNAs  during  the
rocess  of  cardiac  remodelling,  but  the  exact  role  of  miR-
1  in  the  cardiac  stress  response  remains  unclear.  We  did
ot  ﬁnd  any  signiﬁcant  correlation  between  NYHA  functional
lass  and  miR-21  concentrations  in  our  study.  However,
ccording  to  Thum  et  al.  [13],  miR-21  was  highly  expressed
ot  in  myocardiocytes,  but  in  cardiac  ﬁbroblasts,  and  its
xpression  was  higher  with  the  severity  of  HF  exacerbation.
his  miRNA  molecule  was  reported  to  inhibit  the  apopto-
is  of  cardiac  ﬁbroblasts  and  to  enhance  signal  transduction
f  the  mitogen-activated  protein  kinase  signalling  path-
ay,  leading  to  cardiac  hypertrophy  and  myocardial  ﬁbrosis,
hich  are  known  as  important  pathological  factors  impli-
ated  in  the  development  of  HF  [37].  In  preclinical  studies,
ilencing  of  miR-21  function  by  a  speciﬁc  antagomir  in  the
ressure  overload-induced  HF  model  was  able  to  reverse
he  above-mentioned  pathological  processes  and  attenuate
ardiac  dysfunction  [37].  These  observations  suggest  that
iRNA  therapeutic  interventions  might  be  feasible  in  the
hronic  HF  setting.  Of  note,  the  strong  positive  correlation
etween  the  serum  concentrations  of  miR-21  and  galectin-3
emonstrated  in  this  study  conﬁrms  the  postulated  role  of
iR-21  in  ﬁbrosis,  and  constitutes  a  further  validation  of  this
c
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olecule  as  an  attractive  disease  target  in  the  management
f  HF.
In  this  research,  we  did  not  observe  the  expression  of
iR-208a  in  the  plasma  of  control  subjects  or  in  patients,
rrespective  of  their  disease  severity.  The  existing  evidence
n  the  expression  of  this  miRNA  type  is  conﬂicting.  Some
tudies  have  shown  that  miR-208a  has  a  positive  correla-
ion  with  cardiac  ﬁbrosis  in  human  dilated  cardiomyopathy
24]. In  contrast,  Prado-Uribe  et  al.  [38]  demonstrated
hat  expression  of  miR-208a  was  dramatically  decreased,
ut  cardiac  ﬁbrosis  was  markedly  increased,  in  ﬁve  of  six
ephrectomized  rats.  Some  studies  have  also  suggested
hat  miR-208a  is  required  for  stress-induced  cardiac  patho-
hysiological  responses  [39]. In  our  previous  paper,  we
bserved  signiﬁcant  release  of  miR-208a  in  the  early  phase
f  myocardial  infarction  [40]. On  the  other  hand,  Zile  et  al.
41]  demonstrated  late  release  of  miR-208,  5  days  after
cute  myocardial  infarction,  which  remained  up  to  90  days.
his  late  release  is  probably  caused  by  metabolic  changes,
eading  to  left  ventricular  structural  remodelling.  These
onﬂicting  results  may  suggest  that  different  mechanisms
re  responsible  for  the  induction  of  ﬁbrosis  in  human  HF.
hether  miRNA-208a  can  prevent  or  promote  cardiac  ﬁbro-
is  is  still  to  be  determined.  Further  evidence  is  needed  to
dentify  the  role  of  miR-208a  in  cardiac  ﬁbrosis.
uture studies
n  preclinical  studies,  restoration  of  miR-1  concentrations
llowed  for  a  reversal  of  pressure  overload-induced  left  ven-
ricular  hypertrophy  and  attenuation  of  maladaptive  cardiac
emodelling  [42].  Hence,  miR-1  might  also  serve  as  a  target
or  pharmacotherapy.  Nevertheless,  the  diagnostic  accuracy
nd  the  role  of  miR-1  in  the  pathogenesis  of  symptomatic  HF
eed  to  be  determined  in  larger  cohorts  of  patients.
tudy limitations
he  main  limitation  of  this  study  was  its  small  sample  size.
econdly,  we  could  not  assess  the  dynamics  of  the  expres-
ion  of  the  assessed  miRNAs  during  the  course  of  therapy,  as
nly  a  single  measurement  was  taken  on  admission.  Another
imitation  was  the  fact  that  the  association  between  the
nalysed  miRNA  and  left  ventricular  hypertrophy  was  not
valuated.  It  should  be  also  noted  that  neither  healthy
olunteers  nor  subjects  with  non-cardiac  dyspnoea  were
ncluded  in  this  work  and,  as  a  consequence,  we  could  not
erify  whether  miRNA  evaluation  might  allow  for  the  accu-
ate  differentiation  between  cardiac  and  non-cardiac  causes
f  dyspnoea.  Nevertheless,  on  the  basis  of  the  currently
vailable  results  of  miRNA  studies  in  HF  patients,  which  are
ontroversial  because  of  their  high  variability  and  a  rela-
ively  unfavourable  signal-to-noise  ratio,  one  may  suggest
hat  the  most  probable  future  application  of  these  particles
n  HF  diagnostics  will  not  be  associated  with  the  identiﬁca-
ion  of  a  one  disease-speciﬁc  miRNA  type.  Instead,  following
he  concept  of  Goren  et  al.  [26],  it  appears  that  further  stud-
es  aimed  at  determination  of  the  miRNA  ‘set’  or  ‘score’,
onsisting  of  the  most  downregulated  (such  as  miR-1)  and
pregulated  miRNAs,  are  necessary  to  develop  a  diagnostic
ool  that  would  add  valuable  information  to  the  biomarkers
sed  currently  in  HF.
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Conclusions
We  have,  for  the  ﬁrst  time,  demonstrated  that  circulating
miR-1  correlates  with  the  clinical  symptoms  and  biochemi-
cal  signs  of  symptomatic  HF.  Based  on  these  ﬁndings,  miR-1
may  become  a  biomarker  for  predicting  the  exacerbation
of  HF.  miR-1,  in  combination  with  other  biomarkers  of
HF,  may  allow  an  adequate  time  window  for  implementing
appropriate  therapy  and,  as  a  consequence,  preventing  or
attenuating  the  impending  onset  of  acute  HF.  The  observed
correlation  between  miR-21  expression  and  galectin-3  con-
ﬁrms  its  role  in  HF  progression  and  cardiac  remodelling.
Nevertheless,  further  studies  are  necessary  to  evaluate  the
diagnostic  efﬁcacy  of  these  molecules.
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